Institiute gives a boost to five new life science start-ups

Start-up business

Five drug discovery companies have entered the BioInnovation Institute’s (BII) Venture Lab acceleration programme for early-stage companies as part of a cohort of ten new members. 

The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of €500,000 plus access to labs and offices at the BII in Copenhagen.  

In becoming a part of the Venture Lab programme, the early-stage companies also get an exclusive opportunity to apply for €1.4 million in follow-up funding through BII’s Venture House program. 

The new life science companies BII has accepted into the Venture Lab acceleration program are: 

  • AIDA Oncology works to select the best cancer drug for each patient, using the RNA expression pattern of their tumour and machine learning.  
  • Alba Health is on a mission to reduce chronic disease risks from childhood, leveraging data science and the latest microbiome science.  
  • Dawn Bio is a drug discovery platform based on human embryo models for drug development for women’s reproductive health.  
  • METSYSTEM’s unique technology is designed to predict cancer metastasis and determine the optimal chemotherapy to treat it preventively.  
  • Amplify Therapeutics: Disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. 
Supporting innovative science 

Bobby Soni, Chief Business Officer at BioInnovation Institute, said: “BII’s mission is to create products for the welfare of people and society, and we believe that BII’s support of the innovative science in this Venture Lab cohort will deliver on that promise.” 

Each start-up will be supported in undertaking the necessary steps to reach initial proof-of-concept, to make a business plan and to set up a team. Assisted by a dedicated scientific advisor, a leadership coach and a BII business development expert, the new ventures will be guided in developing a detailed milestone plan and will be assisted in overcoming the challenges of growing a business. 

Since its inception in 2018, BII has supported 80 start-ups and projects with €65 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level. In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.  Recent company successes include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free